Pfizer (NYSE:PFE) Stock Price Down 1.5% – Here’s What Happened

Shares of Pfizer Inc. (NYSE:PFE) were down 1.5% during trading on Thursday . The stock traded as low as $27.65 and last traded at $27.83. Approximately 29,190,292 shares traded hands during trading, a decline of 31% from the average daily volume of 42,178,191 shares. The stock had previously closed at $28.24.

Pfizer News Roundup

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer benefited from broader investor enthusiasm surrounding mRNA cancer vaccines after Merck and Moderna reported positive melanoma-trial results. Although Pfizer was not the developer of the reported therapy, the data may support the company’s own cancer-vaccine ambitions and helped lift sentiment toward related drugmakers. Pfizer Stock Rises Wednesday: What’s Going On?
• Positive Sentiment: Pfizer’s potential obesity treatment, berobenatide, is being positioned as a possible monthly competitor to leading GLP-1 medicines. Success could provide a major new growth avenue as older products face patent expirations. Pfizer’s Obesity Push: Can Berobenatide Take Market Share?
• Neutral Sentiment: Pfizer completed a real-world study of Ibrance in women with advanced breast cancer. The update does not yet provide new efficacy results, leaving investors focused on what evidence or regulatory implications may come next. Pfizer’s Ibrance Real-World Breast Cancer Study Wraps Up
• Negative Sentiment: Pfizer’s agreement to settle thousands of Depo-Provera lawsuits involving alleged intracranial meningiomas has renewed concerns about litigation costs, potential liabilities and the company’s legal overhang. Why Is Pfizer Settling Thousands of Legal Claims?
• Negative Sentiment: Analysts describe Pfizer’s outlook as a race between newly launched or acquired medicines and revenue losses from expiring patents. The prospect that replacement products may only offset, rather than exceed, that erosion is limiting enthusiasm for the stock. Pfizer Stock Is a Race Between New Drugs and Old Patents

Analyst Upgrades and Downgrades

Several research analysts have weighed in on the stock. Weiss Ratings lowered shares of Pfizer from a “hold (c)” rating to a “hold (c-)” rating in a research note on Monday. Wolfe Research restated an “underperform” rating and set a $26.00 price target on shares of Pfizer in a report on Thursday, May 14th. JPMorgan Chase & Co. dropped their price target on shares of Pfizer from $30.00 to $28.00 and set a “neutral” rating on the stock in a research note on Wednesday, July 8th. Cantor Fitzgerald reiterated a “neutral” rating and set a $27.00 price objective on shares of Pfizer in a report on Monday, July 6th. Finally, UBS Group reissued a “neutral” rating and set a $27.00 price objective on shares of Pfizer in a research report on Wednesday, May 27th. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, fourteen have assigned a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Hold” and an average target price of $28.28.

Pfizer Price Performance

The company’s 50-day simple moving average is $25.23 and its 200 day simple moving average is $26.23. The company has a market capitalization of $158.62 billion, a P/E ratio of 36.62 and a beta of 0.34. The company has a quick ratio of 0.96, a current ratio of 1.27 and a debt-to-equity ratio of 0.71.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.77 earnings per share for the quarter, beating analysts’ consensus estimates of $0.68 by $0.09. Pfizer had a net margin of 6.80% and a return on equity of 19.63%. The business had revenue of $15.03 billion for the quarter, compared to the consensus estimate of $14.40 billion. During the same quarter last year, the firm earned $0.78 EPS. Pfizer’s revenue for the quarter was up 2.6% on a year-over-year basis. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. As a group, sell-side analysts expect that Pfizer Inc. will post 2.98 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 1st. Shareholders of record on Friday, July 24th will be given a $0.43 dividend. The ex-dividend date of this dividend is Friday, July 24th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.2%. Pfizer’s payout ratio is currently 226.32%.

Institutional Trading of Pfizer

Several large investors have recently made changes to their positions in PFE. Godfrey Financial Associates Inc. bought a new position in shares of Pfizer in the 4th quarter valued at approximately $26,000. Keb Asset Management LLC bought a new stake in Pfizer during the second quarter worth approximately $26,000. Field & Main Bank bought a new stake in Pfizer during the second quarter worth approximately $27,000. HFM Investment Advisors LLC grew its holdings in Pfizer by 61.0% during the fourth quarter. HFM Investment Advisors LLC now owns 1,127 shares of the biopharmaceutical company’s stock valued at $28,000 after purchasing an additional 427 shares during the last quarter. Finally, Evolution Wealth Management Inc. raised its position in shares of Pfizer by 132.2% in the first quarter. Evolution Wealth Management Inc. now owns 994 shares of the biopharmaceutical company’s stock valued at $28,000 after purchasing an additional 566 shares during the period. Institutional investors own 68.36% of the company’s stock.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.